Modified viral vectors and methods of making and using the same
AssigneeuniQure IP B.V.
InventorDavid Johannes Francois DU PLESSIS
Life of this patent
Estimating the term…
Abstract
The present invention relates to production of parvoviral vectors to produce adeno-associated virus (AAV) for gene therapy. In particular the invention relates to improvements in parvoviral vectors that increase the packaging capacity, production efficiency, and infectivity of AAV virions that is necessary for large scale manufacturing of AAV for clinical purposes.
Claims17
An insect cell expressing adeno-associated virus (AAV) VP1 protein and AAV VP3 protein, wherein the insect cell does not express AAV VP2 protein.
A nucleic acid construct, comprising:
- (a) a nucleotide sequence comprising an open reading frame encoding adeno-associated virus (AAV) VP1 protein;
- and
- (b) a nucleotide sequence comprising an open reading frame encoding AAV VP3 protein,
- wherein the open reading frames encoding the AAV VP1 protein and the AAV VP3 protein are operably linked to expression control sequences for expression in an insect cell, and
- wherein AAV VP2 protein cannot be expressed from the nucleic acid construct.
An AAV virion produced in an insect cell, the AAV virion comprising in its genome at least one nucleotide sequence encoding a gene product of interest, wherein the at least one nucleotide sequence is not a native AAV nucleotide sequence, and wherein the AAV virion comprises AAV VP1 protein and AAV VP3 protein and does not comprise AAV VP2 protein.
Dependencies are inferred from the claim text.